Cardiff Oncology, Inc. (CRDF)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CRDF Insider Trading Activity
CRDF Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,011,149 | 5 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| PACE GARY W | director | 1 | $940,199 | 0 | $0 | $940,199 |
| Levine James E. | Chief Financial Officer | 3 | $36,726 | 0 | $0 | $36,726 |
| TANNENBAUM RENEE P | director | 1 | $34,224 | 0 | $0 | $34,224 |
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Activity of Cardiff Oncology, Inc.
Over the last 12 months, insiders at Cardiff Oncology, Inc. have bought $1.01M and sold $0 worth of Cardiff Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cardiff Oncology, Inc. have bought $590,238 and sold $657,020 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PACE GARY W (director) — $940,199. Levine James E. (Chief Financial Officer) — $36,726. TANNENBAUM RENEE P (director) — $34,224.
The last purchase of 2,400 shares for transaction amount of $12,000 was made by Levine James E. (Chief Financial Officer) on 2024‑12‑18.
List of Insider Buy and Sell Transactions, Cardiff Oncology, Inc.
| 2024-12-18 | Levine James E. | Chief Financial Officer | 2,400 0.0041% | $5.00 | $12,000 | -10.47% | ||
| 2024-12-17 | Levine James E. | Chief Financial Officer | 2,752 0.0053% | $5.42 | $14,905 | -24.67% | ||
| 2024-12-16 | Levine James E. | Chief Financial Officer | 2,564 0.0048% | $3.83 | $9,820 | +0.25% | ||
| 2024-12-12 | TANNENBAUM RENEE P | director | 10,000 0.0209% | $3.42 | $34,224 | +23.24% | ||
| 2024-12-11 | PACE GARY W | director | 361,615 0.5003% | $2.60 | $940,199 | +8.92% | ||
| 2023-12-19 | PACE GARY W | director | 30,000 0.0671% | $1.37 | $41,100 | +89.71% | ||
| 2022-11-25 | Erlander Mark | Chief Executive Officer | 10,000 0.0236% | $1.43 | $14,300 | +14.03% | ||
| 2022-09-19 | White Lale | director | 15,000 0.0327% | $1.64 | $24,525 | -7.51% | ||
| 2022-09-16 | Levine James E. | Chief Financial Officer | 30,000 0.0682% | $1.56 | $46,710 | +0.95% | ||
| 2022-09-16 | Armitage James O | director | 13,000 0.0296% | $1.56 | $20,233 | +0.95% | ||
| 2022-09-15 | PACE GARY W | director | 150,000 0.3544% | $1.71 | $256,500 | -4.79% | ||
| 2022-09-15 | TANNENBAUM RENEE P | director | 10,000 0.0237% | $1.72 | $17,168 | -4.79% | ||
| 2021-09-21 | PACE GARY W | director | 30,000 0.0764% | $6.75 | $202,500 | -58.36% | ||
| 2021-09-10 | Levine James E. | Chief Financial Officer | 30,000 0.0779% | $6.47 | $194,000 | -54.92% | ||
| 2021-03-26 | Markin Rodney S | director | 2,900 0.0081% | $10.32 | $29,933 | -37.55% | ||
| 2021-03-23 | PACE GARY W | director | 10,000 0.0273% | $10.23 | $102,300 | -37.74% | ||
| 2021-03-23 | JACOB GARY S | director | 2,370 0.0066% | $10.42 | $24,689 | -37.74% | ||
| 2021-03-23 | Erlander Mark | Chief Executive Officer | 965 0.0027% | $10.34 | $9,980 | -37.74% | ||
| 2021-03-23 | Kelemen Vicki | Exec. VP and COO | 960 0.0026% | $10.31 | $9,898 | -37.74% | ||
| 2021-03-22 | BRANCACCIO JOHN P | director | 3,000 0.0083% | $10.95 | $32,850 | -40.92% |
Insider Historical Profitability
| PACE GARY W | director | 1059376 1.5925% | $3.64M | 9 | 0 | +79.9% |
| Levine James E. | Chief Financial Officer | 67716 0.1018% | $232,943.04 | 5 | 0 | <0.0001% |
| TANNENBAUM RENEE P | director | 20000 0.0301% | $68,800.00 | 2 | 0 | <0.0001% |
| Hunter Robert Merrill | 10 percent owner | 5065004 7.6138% | $17.42M | 1 | 0 | |
| BRIDGER MANAGEMENT, LLC | 2968115 4.4617% | $10.21M | 7 | 0 | <0.0001% | |
| Sheinerman Kira | director | 909090 1.3666% | $3.13M | 1 | 0 | |
| CERRONE GABRIEL | director | 719526 1.0816% | $2.48M | 5 | 0 | |
| White Lale | director | 113788 0.171% | $391,430.72 | 2 | 0 | +295.89% |
| Tennant Stanley | director | 28839 0.0434% | $99,206.16 | 6 | 1 | <0.0001% |
| Erlander Mark | Chief Executive Officer | 24481 0.0368% | $84,214.64 | 4 | 0 | +129.42% |
| Markin Rodney S | director | 23879 0.0359% | $82,143.76 | 3 | 0 | +280.88% |
| JACOB GARY S | director | 21922 0.033% | $75,411.68 | 2 | 0 | +280.78% |
| ZANIBONI STEVE | CFO | 21329 0.0321% | $73,371.76 | 2 | 0 | <0.0001% |
| SCHUH ANTONIUS | CEO | 20000 0.0301% | $68,800.00 | 1 | 0 | <0.0001% |
| ADAMS THOMAS PHD | director | 18875 0.0284% | $64,930.00 | 1 | 2 | +599.3% |
| Armitage James O | director | 13000 0.0195% | $44,720.00 | 3 | 0 | +185.01% |
| BRANCACCIO JOHN P | director | 12260 0.0184% | $42,174.40 | 3 | 0 | +279.19% |
| Kelemen Vicki | Exec. VP and COO | 6053 0.0091% | $20,822.32 | 1 | 1 | <0.0001% |
| WELCH WILLIAM J | CEO | 4750 0.0071% | $16,340.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$7,201,783 | 88 | -8.61% | $225.73M | |
$99,438,720 | 81 | 6.74% | $216.55M | |
$69,130,029 | 69 | 25.63% | $251.19M | |
Cardiff Oncology, Inc. (CRDF) | $17,983,739 | 41 | 102.87% | $228.84M |
$2,545,071 | 34 | 16.59% | $241.88M | |
$18,554,304 | 31 | -11.72% | $236.38M | |
$41,069,367 | 23 | 54.64% | $224.28M | |
$3,513,995 | 18 | -13.04% | $244.61M | |
$46,858,891 | 18 | -11.61% | $237.84M | |
$2,484,989 | 17 | -17.86% | $211.39M | |
$4,701,608 | 14 | -4.34% | $201.32M | |
$11,230,365 | 11 | -45.81% | $204.2M | |
$58,962,528 | 9 | 37.89% | $245.75M | |
$145,296,407 | 8 | -0.98% | $206.47M | |
$335,001 | 6 | -23.71% | $239.92M | |
$55,858,393 | 5 | 14.12% | $207.29M | |
$12,010,220 | 4 | -72.15% | $252.58M | |
$149,309 | 3 | 6.07% | $242.14M | |
$4,888,000 | 3 | -20.50% | $215.78M |
CRDF Institutional Investors: Active Positions
| Increased Positions | 74 | +121.31% | 14M | +111.76% |
| Decreased Positions | 18 | -29.51% | 1M | -10.6% |
| New Positions | 35 | New | 12M | New |
| Sold Out Positions | 3 | Sold Out | 328,330 | Sold Out |
| Total Postitions | 117 | +91.8% | 26M | +101.16% |
CRDF Ownership Change vs Market
Institutional Investor Ownership
| Commodore Capital Lp | $20,192.00 | 8.04% | 5.38M | +5M | New | 2024-12-31 |
| Blackrock, Inc. | $10,653.00 | 4.24% | 2.84M | +105,328 | +3.85% | 2024-12-31 |
| Vanguard Group Inc | $8,568.00 | 3.41% | 2.28M | +113,473 | +5.23% | 2024-12-31 |
| Orbimed Advisors Llc | $5,769.00 | 2.3% | 1.54M | +2M | New | 2024-12-31 |
| Acorn Capital Advisors, Llc | $5,409.00 | 2.15% | 1.44M | +1M | New | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $4,846.00 | 1.93% | 1.29M | +1M | New | 2024-12-31 |
| Geode Capital Management, Llc | $3,686.00 | 1.47% | 982,878 | +54,646 | +5.89% | 2024-12-31 |
| Mai Capital Management | $3,437.00 | 1.37% | 916,587 | +253,224 | +38.17% | 2024-12-31 |
| State Street Corp | $3,182.00 | 1.27% | 848,579 | +15,927 | +1.91% | 2024-12-31 |
| Nuveen Asset Management, Llc | $2,200.00 | 0.88% | 586,616 | +248,850 | +73.67% | 2024-12-31 |